Abstracts tagged "development"

Abstract Number: 1472 • 2019 ACR/ARP Annual Meeting
Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up
MARIA FLORENCIA Rodriguez¹, Anastasia Secco ², Catalan Pellet ³, natalia herscovich ¹, cristina Amitrano ⁴, Cecilia Asnal ⁵, Alejandro Nitsche ⁶, Julia Demarchi ⁷, damian duartes ⁸, Francisco Caeiro ⁹, Veronica Saurit ¹⁰, Nadia Riscanevo ¹¹, Silvia Papasidero ¹², Carla Gobbi ¹³, laura raiti ¹⁴, vanesa cruzat ¹⁴, Lida santiago ¹⁵, Sofia Velez ¹⁶, Gabriela Salvatierra ¹⁷ and Vicente Juarez ¹⁸, ¹hospital rivadavia, buenos aires, Argentina, ²Hospital Rivadavia, Caba, Buenos Aires, Argentina, ³Rivadavia, CABA, Argentina, ⁴Hospital Aleman, CABA, Argentina, ⁵Instituto Centenario, Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Aleman, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁷Hospital Británico, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁸hospital britanico, buenos aires, Argentina, ⁹Hospital Privado de Córdoba, Cordoba, Argentina, ¹⁰Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ¹¹Hospital Privado de Córdoba, Cordoba, Cordoba, Argentina, ¹²Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹³CÁTEDRA DE CLÍNICA MÉDICA I, HOSPITAL CÓRDOBA, FACULTAD DE CIENCIAS MÉDICAS, UNIVERSIDAD NACIONAL DE CÓRDOBA, ARGENTINA, Cordoba, Cordoba, Argentina, ¹⁴clinica bessone, buenos aires, Argentina, ¹⁵OMI, Ciudad Autonoma de Buenos Aires, Argentina, ¹⁶Consultorio Privado S.V, Buenos Aires, Buenos Aires, Argentina, ¹⁷IPRI, Santiago del estero, Santiago del Estero, Argentina, ¹⁸Hospital Milagros de Salta, Salta, Salta, Argentina
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. Is the connective tissue disease that is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].